Biodesix, Inc. (NASDAQ:BDSX) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $35.00.

A number of equities analysts recently commented on BDSX shares. HC Wainwright reiterated a “buy” rating and set a $38.00 price target (up from $27.00) on shares of Biodesix in a report on Friday, September 25th. Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Roth Capital initiated coverage on Biodesix in a research note on Wednesday, June 24th. They set a “buy” rating and a $32.00 target price for the company. Finally, Canaccord Genuity Group lifted their target price on Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, August 10th.

Insider Transactions at Biodesix

In other Biodesix news, Director Jack Schuler purchased 15,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $24.47 per share, with a total value of $367,050.00. Following the acquisition, the director directly owned 555,810 shares of the company’s stock, valued at $13,600,670.70. This trade represents a 2.77% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders acquired 42,600 shares of company stock worth $1,033,062. Company insiders own 23.20% of the company’s stock.

Hedge Funds Weigh In On Biodesix

Large investors have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of Biodesix during the 2nd quarter worth about $112,000. Walleye Capital LLC bought a new position in Biodesix in the 1st quarter valued at about $157,000. Thompson Davis & CO. Inc. bought a new position in Biodesix in the 1st quarter valued at about $170,000. Renaissance Technologies LLC acquired a new stake in Biodesix during the first quarter worth approximately $173,000. Finally, Cetera Investment Advisers lifted its position in Biodesix by 20.0% during the first quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock worth $174,000 after acquiring an additional 2,000 shares during the last quarter. 20.96% of the stock is owned by institutional investors.

Biodesix Stock Performance

Shares of BDSX stock opened at $27.96 on Friday. The stock has a market cap of $294.98 million, a P/E ratio of -8.82 and a beta of 0.56. The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85. The company has a fifty day moving average price of $26.20 and a two-hundred day moving average price of $19.83. Biodesix has a one year low of $5.26 and a one year high of $31.97.

Biodesix (NASDAQ:BDSX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.19. The company had revenue of $26.86 million during the quarter, compared to the consensus estimate of $26.03 million. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. As a group, equities analysts predict that Biodesix will post -2.68 EPS for the current year.

About Biodesix

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of cancer, with an emphasis on lung disease. The company combines blood-based testing, data science and artificial intelligence to help physicians assess cancer risk, guide treatment decisions and monitor patients.

Biodesix’s portfolio includes diagnostic tests for lung nodules and lung cancer, including the Nodify Lung Nodule Risk Assessment suite and blood-based assays such as GeneStrat and VeriStrat.